Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03273049 · ClinicalTrials.gov registry record
Mapping Disease Pathways for Biliary Atresia
A clinical trial of Biliary Atresia, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 1,100
- Enrollment target
- 1
- Study location
NCT03273049: Recruiting study of Biliary Atresia, sponsored by University of Pittsburgh.
NCT03273049 is a study of Biliary Atresia that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 1,100 participants, above the 418-participant average among 7 other Biliary Atresia trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03273049, a study of Biliary Atresia, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 1,100 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.
Primary Outcome
Main project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA.
Conditions Studied
Study Locations (1)
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2016-07-21 |
| Est. Completion | 2035-07-21 |
What NCT03273049 shows while recruiting
NCT03273049 is an observational study that tracks outcomes without assigning an intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 418-participant average among 7 other Biliary Atresia trials with a reported enrollment target (163% higher).
The record links to 1 condition, with Biliary Atresia appearing as the primary indexed condition, and to 0 interventions.
NCT03273049 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03273049 about?
NCT03273049 is a clinical study titled "Mapping Disease Pathways for Biliary Atresia". This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.
What is the current status of trial NCT03273049?
This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2016-07-21. Estimated completion is 2035-07-21.
What conditions does trial NCT03273049 study?
This clinical trial studies the following conditions: Biliary Atresia.
Who is sponsoring clinical trial NCT03273049?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03273049 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Atresia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biliary Atresia Research Network Northeast
RECRUITING
-
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
RECRUITING · Phase 1
-
A Prospective Database of Infants With Cholestasis
RECRUITING
-
Biliary Atresia Study in Infants and Children
RECRUITING
-
The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis
RECRUITING · Early Phase 1
-
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI